Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01852136 · ClinicalTrials.gov registry record
Clinical Evaluation of BD NEXT Pen Needle
A clinical trial, sponsored by Becton, Dickinson and Company.
- Completed
- Registry status
- 217
- Enrollment target
NCT01852136: Completed study, sponsored by Becton, Dickinson and Company.
NCT01852136 is a clinical trial that has completed, run by Becton, Dickinson and Company. The registered enrollment target is 217 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01852136 has completed, sponsored by Becton, Dickinson and Company.
- COMPLETED
- Registry status
- 217 participants
- Enrollment target
Study Summary
This prospective, multi-center, 2 period cross-over study is designed to determine if people who use injection pens for subcutaneous medication delivery prefer the BD NEXT pen needle (PN) in comparison with currently marketed pen needles of the same or similar gauge and length. Subjects will use the investigational (BD NEXT) PN and their usual conventional PN each for one week in a randomly assigned sequence, and will be asked to evaluate and compare characteristics of the BD NEXT pen needle versus their usual pen needle when used for all their pen injections performed at home. Since injection experience may vary according to the type of pen device used, equal numbers of subjects will be recruited who are users of three of the most commonly used insulin pen injectors.
Primary Outcome
The primary objective was assessed using a 15 cm VAS. A vertical line drawn to the left of the VAS center mark indicates that the Study Period 1 PN was preferred more than the Study Period 2 PN. Those PNs will be scored in (-) mm (maximum score -75 mm). A vertical line drawn to the right of the VAS center mark indicates that the Study Period 2 PN was preferred more than the Study Period 1 PN. Those PNs will be scored in (+) mm (maximum score +75 mm). The sign of the reading will be adjusted depe
Interventions
- DEVICE BD NEXT 31G x 5 mm pen needle
- DEVICE BD NEXT 31G x 8mm pen needle
- DEVICE BD NEXT 32G x 4mm pen needle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2012-09 |
| Est. Completion | 2012-12 |
What the finished NCT01852136 record still lists
NCT01852136 is an observational study that tracks outcomes without assigning an intervention. The registered 217 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 3 interventions - of which BD NEXT 31G x 5 mm pen needle is the first listed.
NCT01852136 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01852136 about?
NCT01852136 is a clinical study titled "Clinical Evaluation of BD NEXT Pen Needle". This prospective, multi-center, 2 period cross-over study is designed to determine if people who use injection pens for subcutaneous medication delivery prefer the BD NEXT pen needle (PN) in comparison with currently marketed pen needles of the same or similar gauge and length. Subjects will use the...
What is the current status of trial NCT01852136?
This trial is currently completed. The enrollment target is 217 participants. The study started on 2012-09. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01852136?
The interventions under investigation include: BD NEXT 31G x 5 mm pen needle (DEVICE), BD NEXT 31G x 8mm pen needle (DEVICE), BD NEXT 32G x 4mm pen needle (DEVICE).
Who is sponsoring clinical trial NCT01852136?
This trial is sponsored by Becton, Dickinson and Company, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05079282 · 217 participants · Phase 1
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
- NCT05470439 · 217 participants · NA
My Interprofessional Care Team for Adherence and Research Engagement Disparities
- NCT05981703 · 217 participants · Phase 1
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- NCT06342258 · 217 participants · Phase 1
COES: Curing Order Effects on Sealants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia